Barr Labs up 1 1/16 today. Net income up by almost 100% excluding Warfarine launch expenses. Lay back and enjoy.
Barr Labs 4Q Net 2c A Share 7c
Barr Laboratories Inc. - Pomona, N.Y.
4th Quar June 30:
1997 1996
Revenues $65,706,000 $60,495,000
Net income a 527,000 1,682,000
Avg shrs (primary) 22,884,000 22,218,000
Avg shrs (diluted) 23,035,000 22,218,000
Shr earns (primary)
Net income a .02 .07
Shr earns (diluted)
Net income a .02 .07
a. Included costs of $2.5 million related to the company's Warfarin product and a
$1.2 million increase in spending on research and development.
Year June 30:
1997 1996
Revenues $284,486,000 $232,224,000
Net income a 19,447,000 $7,016,000
Avg shrs (primary) 22,430,000 21,757,000
Avg shrs (diluted) 22,906,000 22,140,000
Shr earns (primary)
Net income a .87 .32
Shr earns (diluted)
Net income a .85 .32
a. Included costs of $2.5 million related to the company's Warfarin product and a
$1.2 million increase in spending on research and development.
Barr Laboratories Inc. (BRL) said a continued increase in demand for its
Tamoxifen breast cancer treatment, and increased sales contributions from its
new products including Danazol, Medroxyprogesterone and Meperidine, helped
this year's net product sales.
Barr Laboratories develops generic drugs to treat diseases and conditions like
cancer, heart disease, depression and hypertension.
Barr Laboratories Inc. (BRL) reported revenues of $284,486,000 for the year ended
June 30.
(In an item at 10:16 a.m. EDT, the 1997 revenues were misstated.) |
